Acambis PLC - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Acambis PLC Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Acambis PLC. The Group's principal activity is researching, developing and manufacturing vaccines to prevent and treat infectious diseases. The Group's vaccine product are ChimeriVax-JE and ChimeriVax-West Nile. ChimeriVax-JE is a single-dose vaccine for travellers and those living in endemic regions. ChimeriVax-West Nile focuses on viruses transmitted to humans and animals by the bite of an infected mosquito. The Group's other pipeline products are Clostridium difficile and Influenza vaccine. The Group operates in the United Kingdom and the United States of America.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report